Duquesne Family Office’s Recursion Pharmaceuticals RXRX Stock Holding History

Duquesne Family Office’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-906,767	Closed	-$8.94M	–	87
2023 Q4	$8.94M	Hold	906,767	–	–	0.27%	42
2023 Q3	$6.94M	Sell	906,767 -479,183	-35%	-$4.78M	0.25%	32
2023 Q2	$10.4M	Hold	1,385,950	–	–	0.36%	37
2023 Q1	$9.26M	Hold	1,385,950	–	–	0.4%	31
2022 Q4	$10.7M	Hold	1,385,950	–	–	0.53%	33
2022 Q3	$14.7M	Buy	1,385,950 +1,112,300	+406%	+$11.3M	0.84%	29
2022 Q2	$2.23M	Hold	273,650	–	–	0.16%	33
2022 Q1	$1.96M	Buy	273,650 +13,709	+5%	+$146K	0.09%	47
2021 Q4	$4.45M	Hold	259,941	–	–	0.16%	41
2021 Q3	$5.98M	Buy	+259,941	New	+$7.37M	0.19%	40

Other funds holding RXRX

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MIC

Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Duquesne Family Office's RXRX Position: Q1 2024 in Review

Duquesne Family Office sold out of Recursion Pharmaceuticals (RXRX) in Q1 2024, closing a stake of 906,767 shares — an estimated $8.94M sold.

Duquesne Family Office first reported a position in RXRX in Q3 2021 and held it in 10 quarters. The position peaked at $14.7M in Q3 2022. 249 funds tracked by Wall St. Rank hold RXRX as of Q1 2024.

Duquesne Family Office reported no remaining Recursion Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Duquesne Family Office sold 906,767 Recursion Pharmaceuticals shares in Q1 2024, an estimated $8.94M.
Duquesne Family Office first reported a position in Recursion Pharmaceuticals in Q3 2021 and held it in 10 quarters.
Duquesne Family Office's Recursion Pharmaceuticals position peaked at $14.7M in Q3 2022.
249 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2024.

Based on Duquesne Family Office's 13F filing for Q1 2024, filed 15 May 2024.